1.Preliminary analysis on genetic variation of Iphigenia indica by RAPD
Chinese Traditional and Herbal Drugs 1994;0(06):-
Object To study on the genetic diversity and genetic structure of Iphigenia indica Kunth. Methods Random amplified polymorphic DNA (RAPD) was applied to detect DNA fingerprints of three populations of I. indicafrom Yunnan Province. Results Twenty primers were screened, and a total of 120 DNA fragments were amplified ranging from 0.2-3 kb, among which 71 (59.17%) were polymorphic. The average number of DNA band produced by each primer was 3.55. The Shannon index was (0.199 4) in Ca population, 0.200 7 in Cb population, 0.254 8 in Cc population, respectively; the average value of populations was 0.218 3. The Shannon index was 0.288 6 in species. Nei's genetic identity was 0.930 9 between Ca and Cb, 0.932 7 between Ca and Cc, 0.946 6 between Cb and Cc. G_(st) within population was (0.204 4.) Conclusion For the establishment of protective tactic and measure, and of the standard of good agriculture practice (GAP) growth and heredity breeding, RAPD analysis provides I. indicawith theoretical foundation and basal data.
2.Development and management of the information management system of metabolic disorder biobanks
Chinese Journal of Medical Science Research Management 2013;(3):204-206,209
Metabolic diseases information consulting provides its clients with data and insight to help translation information medicine product development plans:for clinical,diagnosis,biologics,medical devices/combination products.Understanding the mechanisms by which specific protein functions contribute to metabolic disease pathogenesis is a great challenge.The barcode is the common nominator and identifier of a sample.This code can be utilized in both 2D form,capturing important identifiers for each sample type and origin.Visual database informational system,to impact on the quality of the analysis data generated.Our ultimate motivation lies in helping you to advance the translation medicine success of our hospital,and to optimize the benefit they provide to patients in need.
3.Lead compound optimization strategy (4)--improving blood-brain barrier permeability through structural modification.
Yu HONG ; Yu ZHOU ; Jiang WANG ; Hong LIU
Acta Pharmaceutica Sinica 2014;49(6):789-799
Blood-brain barrier is a natural protection for human body. It protects central nervous system from the interruption and damage of xenobiotics. However, it prevents potential drugs aimed at central nervous system, thus becomes an obstruction for the development of central nervous system drugs. The recent development of blood-brain barrier permeability research and several lead optimization strategies to improve blood-brain barrier permeability are reviewed. These structure optimization methods include increasing lipophilicity, reducing hydrogen bond doners, simplifying molecule, increasing rigidity, lowering polar surface area, avoiding acid group, prodrug strategy, modifying into active transporter's substrates, as well as avoiding P-glycoprotein recognized structures.
ATP-Binding Cassette, Sub-Family B, Member 1
;
metabolism
;
Biological Transport
;
Blood-Brain Barrier
;
Central Nervous System
;
drug effects
;
Central Nervous System Agents
;
pharmacokinetics
;
Drug Design
;
Humans
;
Permeability
;
Xenobiotics
;
adverse effects
4.Lead compound optimization strategy (4)--improving blood-brain barrier permeability through structural modification.
Yu HONG ; Yu ZHOU ; Jiang WANG ; Hong LIU
Acta Pharmaceutica Sinica 2014;49(6):789-99
Blood-brain barrier is a natural protection for human body. It protects central nervous system from the interruption and damage of xenobiotics. However, it prevents potential drugs aimed at central nervous system, thus becomes an obstruction for the development of central nervous system drugs. The recent development of blood-brain barrier permeability research and several lead optimization strategies to improve blood-brain barrier permeability are reviewed. These structure optimization methods include increasing lipophilicity, reducing hydrogen bond doners, simplifying molecule, increasing rigidity, lowering polar surface area, avoiding acid group, prodrug strategy, modifying into active transporter's substrates, as well as avoiding P-glycoprotein recognized structures.
5.Effect of methazolamide in patients with refractory uveitic macular edema
Yun-Bin, JIANG ; Hong, ZHU ; Yu-Hong, CHEN ; Hong, WANG
International Eye Science 2017;17(7):1359-1361
AIM:To evaluate the efficacy and safety of methazolamide in treating refractory uveitic macular edema.METHODS: Retrospective self-controlled study was designed.A total of 15 patients (20 eyes) with refractory uveitic macular edema which used methazolamide as adjuvant therapy were enrolled in Shanghai First People`s Hospital from January 2015 to June 2016.The changes of central macular thickness (CMT) and best corrected visual acuity (BCVA) were observed at baseline and 2, 4, 8wk after treatment.We also focused on the incidence of complications and relapse.RESULTS: The CMT was 445.95±154.10μm, 338.83±138.34μm, 251.50±40.20μm, 244.90±35.68μm at baseline, 2, 4 and 8wk after treatment, respectively.The differences among them were statistically significant (F=15.467, P<0.05).The BCVA (log MAR) were 0.40±0.17, 0.28±0.21, 0.19±0.20, 0.18±0.21 at baseline, 2, 4 and 8wk respectively, with a significant difference among them (F=5.208, P<0.05).When the cumulative dose reached to 700mg and 1400mg, no one had methazolamide-related complications;and when it came to 2800mg, 5 patients (33%) had methazolamide-related complication.After the withdrawal of methazolamide 1wk, 1 and 3mo, 3 patients (20%), 5 patients (33%) and 8 patients (53%) relapsed, respectively.CONCLUSION: Methazolamide is beneficial in improving macular edema and vision in 4wk.When the cumulative dose is more than 1400mg, we need pay attention to the complications.After discontinuing methazolamide for 1wk, macular edema relapsed in some patients, and more than half of patients recurred after 3mo.So the patients should be followed closely in 3mo after withdrawal of methazolamide.
6.A randomized controlled trial of the efficacy of combination of gemcitabine and carboplatin or paclitaxel and combination of paclitaxel and carboplatin in the treatment for advanced non-small cell lung cancer.
Qing GAO ; Fu-yuan WANG ; Hong YU
Chinese Journal of Oncology 2011;33(11):874-876
Adult
;
Aged
;
Aged, 80 and over
;
Anemia
;
chemically induced
;
Antineoplastic Combined Chemotherapy Protocols
;
adverse effects
;
therapeutic use
;
Carboplatin
;
administration & dosage
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
pathology
;
Deoxycytidine
;
administration & dosage
;
analogs & derivatives
;
Female
;
Follow-Up Studies
;
Humans
;
Leukopenia
;
chemically induced
;
Lung Neoplasms
;
drug therapy
;
pathology
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Paclitaxel
;
administration & dosage
;
Remission Induction
;
Survival Rate
;
Thrombocytopenia
;
chemically induced
8.Operation Coordination for the da Vinci Robot Surgical System
Xiaofen YU ; Zhifei WANG ; Min HONG
Chinese Journal of Minimally Invasive Surgery 2015;(6):570-573
[Summary] This paper reported the surgical cooperation in 72 cases of da Vinci robot operations between September 2014 and December 2014 in this hospital .All the 72 cases of total laparoscopic operation by using the da Vinci robot assistance were successfully completed, without robot faults caused by mismatch and nursing complications caused by improper nursing .We believe that nurse training with robot surgical system and qualification certification , preoperative patient visits , reasonable arrangement of operation room , careful observation with skilled coordination with the robot , proper postoperative placement of the robot , and maintenance and disinfection of the machine are crucial to a successful surgery .
9.Determination of Residual Organic Solvents in Imported Lidocaine Patches by GC
Qunyang YU ; Hong WANG ; Huizhuang ZHU
China Pharmacist 2016;19(2):377-378,379
Objective:To establish a GC method for the determination of residual organic solvents in lidocaine patches. Methods:GC was carried out on a DB-WAX capillary column (30 m × 0. 25 mm, 0. 5 μm). The detector was FID and the carrier gas was He. The initial temperature was 50℃, maintained for 8 min, and then raised to 250℃ with a rate of 50℃ per min. The inlet temperature and the detector temperature were 280℃. The separation was 50 ∶1. Results:The linear range of acetone, ethyl acetate and methanol was 15. 0-600. 0 μg·ml-1. The average recovery was 97. 4% (RSD =3. 2%, n=9), 95. 6% (RSD=1. 9%, n=9) and 112. 0%(RSD =4. 5%, n=9), respectively. Conclusion:The method is simple and accurate,which can be used for the determination of re-sidual organic solvents in lidocaine patches.
10.Evaluation on clinical efficacy of hyperbaric oxygenation in treatment of sudden deafness :A Meta-analysis
Ranyang MA ; Hong YU ; Xin WANG
Journal of Jilin University(Medicine Edition) 2017;43(2):298-305
Objective:To evaluate the clinical efficacy of treatment of sudden deafness using hyperbaric oxygenation, and to provide guidance for its treatment. Methods:The studies about sudden deafness treated with hyperbaric oxygenation combined with drug were retrieved in Cochrane Library, PubMed , MEDLINE, Wanfang Database and CNKI up to July 2016.RavMan 5.3 provided by Cochrane was used for Meta-analysis.Results:Thirty-nine studies which were randomized controlled trials (RCTs)were included, a total of 4 599 cases,of which 2 418 cases received hyperbaric oxygenation therapy combined with drug treatment as treatment group and 2 181 cases received drug treatment alone as control group.A total of 36 studies about the comparison of clinical efficacy between treatment group and control group were included in the Meta-analysis, the result showed that treatment group had a significant clinical efficacy than control group(RR:1.26,95%CI:1.22-1.30,P<0.0001).A total of 6 studies about the improvement of the pure tone average(PTA)in the two groups were included in the Meta-analysis, the PTA gain was significant better in hyperbaric oxygenation group(WMD:11.8,95%CI:4.77-18.83,P<0.000 1).A total of 11 studies about the stage of using hyperbaric oxygenation therapy were included in the Meta-analysis, the result suggested that the early use of hyperbaric oxygenation therapy had better effect than the late use of hyperbaric oxygenation (RR:1.42,95%CI:1.31-1.53,P<0.000 01).Conclusion:The clinical efficacy of hyperbaric oxygenation combined with drug therapy is better than drug therapy alone, the PTA gain is significantly improved and the introduction of hyperbaric oxygenation therapy at the earlier stage shows better results.